Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.
Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.
Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.
Capricor Therapeutics (NASDAQ: CAPR) announced positive preclinical results for its novel exosome-based mRNA vaccine for COVID-19, developed in collaboration with Johns Hopkins University. The vaccine shows potential in inducing long-lasting immunity to multiple SARS-CoV-2 proteins. Key findings include a safe exosome formulation that delivers functional mRNA and generates persistent cellular immune responses. Capricor plans to schedule a pre-IND meeting with the FDA to discuss clinical development strategies. The company reported a net loss of approximately $3.9 million for Q3 2020 with $35.3 million in cash on hand.
Capricor Therapeutics (NASDAQ: CAPR) will announce its third-quarter financial results for 2020 after market close on November 12, 2020. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update.
Capricor focuses on developing cell and exosome-based therapeutics, with its lead candidate, CAP-1002, targeting Duchenne muscular dystrophy and COVID-19 cytokine storms. The company is also exploring exosome vaccines for COVID-19.
On September 23, 2020, Capricor Therapeutics (NASDAQ: CAPR) announced that it will present data from the Phase II HOPE-2 clinical trial for its lead product CAP-1002, targeting Duchenne muscular dystrophy (DMD), at the World Muscle Society Virtual Congress on October 1. The trial showed significant improvements in upper limb, cardiac, and respiratory functions after 12 months of treatment, with p-values less than 0.05. CEO Dr. Linda Marbán emphasized the importance of this therapy for DMD patients, as treatment options remain limited and a pathway for potential FDA approval is under discussion.
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, announced that CEO Linda Marbán, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 10:30 AM ET. Capricor specializes in first-in-class cell and exosome-based therapeutics aimed at treating diseases such as Duchenne muscular dystrophy and COVID-19. The presentation will be accessible via webcast, providing insights into the company's innovative approaches and ongoing clinical developments.
Capricor Therapeutics (NASDAQ:CAPR) announced its presentation at the LD 500 investor conference on September 4, 2020, at 9:20 AM ET. CEO Linda Marbán will present to a virtual audience, reflecting on the challenges of COVID-19 in hosting physical events. The LD 500, taking place from September 1-4, is designed to be accessible to everyone, showcasing unique companies in the microcap market. Capricor focuses on cell and exosome-based therapeutics, with lead candidate CAP-1002 in development for Duchenne muscular dystrophy and COVID-19.
Capricor Therapeutics (NASDAQ: CAPR) announced FDA acceptance of its IND application for a Phase 2 clinical trial of CAP-1002 targeting COVID-19. The INSPIRE Trial will enroll 60 patients requiring supplemental oxygen across diverse U.S. sites. The trial aims to evaluate the safety and efficacy of CAP-1002, which has shown promise in managing cardiac complications from COVID-19. Capricor focuses on innovative cell and exosome-based therapies for various diseases, with CAP-1002 also under investigation for Duchenne muscular dystrophy.
Capricor Therapeutics (NASDAQ: CAPR) reported positive progress in its COVID-19 and Duchenne Muscular Dystrophy (DMD) programs. The company is advancing an exosome-based mRNA vaccine capable of generating antibody responses against COVID-19, currently in animal studies. A Phase II IND for CAP-1002 targeting severe COVID-19 patients has been submitted to the FDA. Financially, Capricor experienced a net loss of $3.5 million for Q2 2020, but increased cash reserves to $36.3 million following a $29.4 million capital raise. The company plans to host a conference call to discuss these developments.
Capricor Therapeutics (NASDAQ: CAPR) will release its second quarter financial results for 2020 on August 6, 2020, after market close. Management will hold a conference call at 4:30 p.m. ET to discuss the results and provide a business update. The company is focused on developing innovative cell and exosome-based therapeutics, including its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy and COVID-19. Investors can participate via a toll-free call or a webcast available on the company’s website.
Capricor Therapeutics (NASDAQ: CAPR) announced its participation in the upcoming BIO Digital International Convention from June 8-12, 2020. The event, transitioning to a virtual format, will connect global biotech partners through one-on-one meetings and educational resources. Capricor focuses on developing innovative biological therapeutics, including its lead candidate CAP-1002 for treating Duchenne muscular dystrophy and COVID-19. For more details, visit Capricor's Investor Relations page.
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, announced CEO Linda Marbán's participation in a panel on cell therapy for ARDS on May 27 at 10:00 AM ET. This discussion, part of a session hosted by Maxim Group and M-Vest, will address the role of cell therapy in treating acute respiratory distress syndrome, particularly in the context of COVID-19. Capricor is developing CAP-1002, a cell therapy for Duchenne muscular dystrophy and COVID-19, while also exploring exosome-based treatments. The company emphasizes its commitment to innovation in biological therapeutics.
